Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei ET22
- Development stage
- Unknown
- Lead developer
- Yili
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus paracasei ET22 is a specific probiotic bacterial strain being investigated for its therapeutic potential in managing halitosis (oral malodor). Developed by researchers at China Agricultural University, the strain is typically administered in the form of lozenges containing either live or heat-killed (postbiotic) cells. The mechanism of action involves the modulation of the oral microbiota to suppress the growth of anaerobic bacteria that produce volatile sulfur compounds (VSCs), such as hydrogen sulfide and methyl mercaptan, which are the primary chemical drivers of bad breath. Clinical evaluation of ET22 focuses on reducing VSC levels as measured by Halimeter readings and improving the overall diversity and composition of the salivary microbiome.
- Other names
- Lactobacillus paracasei ET22L. paracasei ET22Lacticaseibacillus paracasei ET22
Beyond the preview
Go deeper on Lactobacillus paracasei ET22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei ET22.